CRISPR Therapeutics AG (CRSP)
49.78
-1.74
(-3.38%)
USD |
NASDAQ |
Oct 16, 12:42
CRISPR Therapeutics SG&A Expense (TTM) : 70.07M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 70.07M |
| March 31, 2026 | 71.43M |
| December 31, 2025 | 73.54M |
| September 30, 2025 | 73.27M |
| June 30, 2025 | 73.76M |
| March 31, 2025 | 74.32M |
| December 31, 2024 | 72.98M |
| September 30, 2024 | 71.33M |
| June 30, 2024 | 72.20M |
| March 31, 2024 | 71.76M |
| December 31, 2023 | 76.16M |
| September 30, 2023 | 80.85M |
| June 30, 2023 | 89.56M |
| March 31, 2023 | 96.80M |
| December 31, 2022 | 102.46M |
| September 30, 2022 | 105.42M |
| June 30, 2022 | 102.77M |
| March 31, 2022 | 106.31M |
| December 31, 2021 | 102.80M |
| September 30, 2021 | 104.44M |
| June 30, 2021 | 101.63M |
| March 31, 2021 | 93.18M |
| Date | Value |
|---|---|
| December 31, 2020 | 88.21M |
| September 30, 2020 | 79.71M |
| June 30, 2020 | 73.69M |
| March 31, 2020 | 68.11M |
| December 31, 2019 | 63.49M |
| September 30, 2019 | 62.76M |
| June 30, 2019 | 57.41M |
| March 31, 2019 | 54.39M |
| December 31, 2018 | 48.29M |
| September 30, 2018 | 43.08M |
| June 30, 2018 | 41.01M |
| March 31, 2018 | 36.04M |
| December 31, 2017 | 35.84M |
| September 30, 2017 | 36.60M |
| June 30, 2017 | 32.60M |
| March 31, 2017 | 33.58M |
| December 31, 2016 | 31.06M |
| September 30, 2016 | 21.11M |
| June 30, 2016 | 19.58M |
| March 31, 2016 | 10.83M |
| June 30, 2015 | 4.711M |
| March 31, 2015 | 2.572M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 2.008B |
| Basilea Pharmaceutica AG | 45.60M |
| Santhera Pharmaceuticals Holding AG | 18.92M |
| BeOne Medicines Ltd. | 2.238B |
| AC Immune SA | 19.51M |